Clinical Trial

Risk Factors Affecting Growth in Thalassemic Children at AUCH

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.
Trial Details
NCT Number NCT07509996
Lead Sponsor Assiut University
Conditions Thalassemia Majors (Beta-Thalassemia Major)
Enrollment 85 participants
Start Date 2026-04-01
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-03